Compound Evidence File
#EC-2026-0622
DNP
Filed under Oral Tablets. The bureau holds 164 laboratory returns for this compound from 55 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
55 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 7 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 6 | 10.0 | 10.0 | 10.0 | 23 May 2026 | 23 May 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 4 | 10.0 | 10.0 | 10.0 | 13 Dec 2025 | 17 Jun 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 4 | 10.0 | 9.9 | 10.0 | 21 Apr 2026 | 19 Aug 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 3 | 10.0 | 10.0 | 10.0 | 27 Dec 2025 | 24 Jun 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 2 | 10.0 | 10.0 | 10.0 | 14 Nov 2025 | 17 May 2026 |
| BachemCASE #VI-2026-0314 | A | 2 | 10.0 | 10.0 | 10.0 | 5 May 2026 | 1 Jun 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 2 | 10.0 | 10.0 | 10.0 | 25 Dec 2025 | 23 Feb 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 4 | 9.9 | 9.9 | 10.0 | 24 Feb 2026 | 6 Jul 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 4 | 9.9 | 9.9 | 10.0 | 19 Nov 2025 | 11 Jul 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 4 | 9.9 | 9.9 | 10.0 | 21 Jan 2026 | 2 Jul 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 4 | 9.9 | 9.9 | 10.0 | 2 Jan 2026 | 9 Jun 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 4 | 9.9 | 9.9 | 10.0 | 25 Mar 2026 | 25 Jun 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 4 | 9.9 | 9.9 | 10.0 | 9 Feb 2026 | 4 Aug 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 3 | 9.9 | 9.9 | 10.0 | 19 Mar 2026 | 2 Jul 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 3 | 9.9 | 9.9 | 10.0 | 9 Mar 2026 | 24 May 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 3 | 9.9 | 9.9 | 9.9 | 9 Apr 2026 | 27 Jul 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 2 | 9.9 | 9.9 | 10.0 | 13 Apr 2026 | 8 Jul 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 2 | 9.9 | 9.9 | 9.9 | 13 Mar 2026 | 7 May 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 2 | 9.9 | 9.9 | 10.0 | 16 Mar 2026 | 1 May 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 2 | 9.9 | 9.9 | 10.0 | 14 Jun 2026 | 17 Jul 2026 |
| SinoPepCASE #VI-2026-0387 | A | 2 | 9.9 | 9.9 | 10.0 | 9 Dec 2025 | 15 May 2026 |
| AsymchemCASE #VI-2026-0091 | A | 2 | 9.9 | 9.9 | 9.9 | 16 Apr 2026 | 14 May 2026 |
| Shanghai JinBei Chemical TechnologyCASE #VI-2026-0107 | X | 1 | 9.5 | 9.5 | 9.5 | 2 Apr 2025 | 2 Apr 2025 |
| Precision Peptide CoCASE #VI-2026-0559 | X | 1 | 9.2 | 9.2 | 9.2 | 16 Mar 2025 | 16 Mar 2025 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 5 | 8.9 | 7.7 | 10.0 | 23 May 2026 | 23 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 6 | 8.5 | 6.4 | 10.0 | 24 May 2026 | 24 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 2 | 8.4 | 8.1 | 8.7 | 24 May 2026 | 24 May 2026 |
| Xingtai Pukelai Technology CoCASE #VI-2026-0850 | X | 1 | 8.4 | 8.4 | 8.4 | 27 Feb 2025 | 27 Feb 2025 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 8 | 8.3 | 6.5 | 10.0 | 24 May 2026 | 24 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 8 | 8.1 | 6.9 | 9.6 | 24 May 2026 | 24 May 2026 |
| Peptide PartnersCASE #VI-2026-0295 | X | 5 | 8.0 | 6.5 | 9.3 | 13 Jun 2025 | 25 May 2026 |
| BeiBangAnCASE #VI-2026-0899 | X | 2 | 7.8 | 7.8 | 7.9 | 3 Jun 2025 | 24 May 2026 |
| Aavant ResearchCASE #VI-2026-0831 | X | 1 | 7.7 | 7.7 | 7.7 | 9 Jun 2025 | 9 Jun 2025 |
| Polaris PeptidesCASE #VI-2026-0839 | X | 7 | 7.4 | 5.4 | 9.1 | 27 Feb 2025 | 17 May 2026 |
| ZLZ PeptideCASE #VI-2026-0524 | X | 5 | 7.0 | 5.4 | 8.0 | 8 Jul 2025 | 24 May 2026 |
| HkRoidsCASE #VI-2026-0784 | X | 1 | 6.7 | 6.7 | 6.7 | 24 Apr 2025 | 24 Apr 2025 |
| Alpha-GenCASE #VI-2026-0905 | X | 2 | 6.5 | 6.0 | 7.0 | 21 May 2025 | 17 May 2026 |
| Elite Research USACASE #VI-2026-0267 | X | 1 | 6.4 | 6.4 | 6.4 | 3 Jul 2025 | 3 Jul 2025 |
| Zenith Jove Peptide ZJCASE #VI-2026-0570 | X | 2 | 6.2 | 5.5 | 7.0 | 17 Dec 2024 | 19 Jan 2026 |
| Peptide SciencesCASE #VI-2026-0867 | X | 11 | 6.1 | 2.9 | 8.3 | 8 Jul 2025 | 21 May 2026 |
| Paramount PeptidesCASE #VI-2026-0550 | X | 5 | 6.1 | 4.7 | 7.9 | 6 May 2025 | 20 May 2026 |
| Diju Peptides Wellness and CoCASE #VI-2026-0724 | X | 1 | 6.1 | 6.1 | 6.1 | 8 Jul 2025 | 8 Jul 2025 |
| Wolverine PeptidesCASE #VI-2026-0262 | X | 1 | 6.1 | 6.1 | 6.1 | 11 Jun 2025 | 11 Jun 2025 |
| LN PeptidesCASE #VI-2026-0781 | X | 1 | 6.0 | 6.0 | 6.0 | 3 Jul 2025 | 3 Jul 2025 |
| PeptiLab ResearchCASE #VI-2026-0267 | X | 1 | 5.7 | 5.7 | 5.7 | 27 Feb 2025 | 27 Feb 2025 |
| Loti LabsCASE #VI-2026-0171 | X | 2 | 5.5 | 4.7 | 6.2 | 3 Jul 2025 | 25 May 2026 |
| Eternal PeptidesCASE #VI-2026-0842 | X | 1 | 5.2 | 5.2 | 5.2 | 11 Jun 2025 | 11 Jun 2025 |
| ZZQ PeptidesCASE #VI-2026-0550 | X | 1 | 5.1 | 5.1 | 5.1 | 8 Jul 2025 | 8 Jul 2025 |
| Coastal PeptidesCASE #VI-2026-0958 | X | 1 | 5.1 | 5.1 | 5.1 | 2 Apr 2025 | 2 Apr 2025 |
| Peptides 4 ResearchCASE #VI-2026-0511 | X | 2 | 4.2 | 3.9 | 4.4 | 2 Jul 2025 | 17 May 2026 |
| Shaanxi Dideu MedichemCASE #VI-2026-0499 | X | 1 | 3.8 | 3.8 | 3.8 | 24 Apr 2025 | 24 Apr 2025 |
| Alimo PeptideCASE #VI-2026-0524 | X | 1 | 3.4 | 3.4 | 3.4 | 7 May 2025 | 7 May 2025 |
| Wuhan Newtop BiotechCASE #VI-2026-0676 | X | 1 | 1.5 | 1.5 | 1.5 | 27 Feb 2025 | 27 Feb 2025 |
| Marvel PeptideCASE #VI-2026-0507 | X | 1 | 0.5 | 0.5 | 0.5 | 6 May 2025 | 6 May 2025 |
Open any subject to view the batch-level evidence for DNP alone.